If a peer-reviewed paper bears out the news story, “It’s one more step on the path to potential clinical application,” says bioethicist Jeffrey Kahn of Johns Hopkins Berman Institute of Bioethics, who served on a committee convened by the NASEM to address gene editing. The panel’s report earlier this year concluded that a clinical trial involving embryo editing would be ethically allowable under narrow circumstances.

Quick Read

Panel recommends scrapping proposed changes to ‘Common Rule’ on human-subjects research

Quick Read

‘The virus is winning hands down’ keynote speaker Michael Osterholm says, urges more action, investment in vaccine research. Panel included our Nancy Kass

Read More